U.S.-based biotechnology company Cirius Therapeutics has offered to sell its shares to the public.
Cirius Therapeutics will collect approximately $86 million in the stock market listing.
With the net funds, Cirius Therapeutics will enhance the developing a treatment for nonalcoholic steatohepatitis with fibrosis and phase 2b trial results.
Cirius Therapeutics has raised a total of $49 million in funding over 2 rounds.